People describe food noise going quiet on a GLP-1 medication as one of the most disorienting parts of treatment because the contrast reveals how much mental space food occupied before treatment. Food noise is a subjective report about food-related thoughts and urges. Brain imaging studies measure a separate signal, the BOLD response to food cues during treatment. The evidence on what happens to those subjective reports after treatment stops is less developed than the weight-regain data.
01How GLP-1 trials measure food noise
Food noise is not a diagnostic term and it never appears in a DSM code or a lab value. It is a patient-generated phrase for a felt experience, the sense that food occupies more mental space than the situation calls for. Researchers approximate it with several different instruments that do not always move together: hunger and fullness visual analog scales, the Food Craving Inventory, the Power of Food Scale, the Control of Eating Questionnaire, and directly observed ad libitum energy intake at a test meal.
Those instruments capture different pieces of the same system. A person can report lower hunger on a visual analog scale while their Power of Food Scale score, which measures preoccupation with palatable food that is present but not yet eaten, stays flat. Another person can show reduced test-meal intake without any change in self-reported craving. Treat "food noise went down" as a summary of several possible shifts, not a single measured outcome, and ask which instrument, if any, actually moved before accepting the claim as evidence rather than description.
The clinical trials that come closest to measuring the construct directly still show large effects. Food noise already covers the strongest of these numbers: a 2019 trial of 113 adults found liraglutide plus behavioral treatment cut food preoccupation scores far more than behavioral treatment alone by week 6, and a 2025 randomized trial found tirzepatide dropped Food Craving Inventory and Power of Food Scale scores by week 3, with test-meal energy intake 72% below baseline by week 6.45 Those are the clearest human data connecting a GLP-1 drug to the subjective experience people call food noise.
02The reward circuit behind food noise
Appetite runs on two systems that feel identical from the inside but operate on different signals. The homeostatic system tracks energy balance through ghrelin, leptin, and hypothalamic signaling, and it is what satiety is built to switch off. The hedonic system tracks reward value through mesolimbic dopamine circuits that respond to food cues, palatability, and availability regardless of energy status. Hedonic hunger covers this distinction in more depth. Food noise sits closer to the hedonic side as a working description. It can occur alongside reward-circuit activity that assigns value to food after energy needs are met, though imaging studies do not establish a direct one-to-one link between that activity and the subjective report.
Human imaging work has mapped several nodes in that circuit. A 2014 fMRI study of 48 participants found that GLP-1 receptor activation changed activity in the insula and amygdala, regions that process the salience and emotional weight of a food cue before any decision to eat gets made.6 The insula and putamen also showed reduced response to food pictures in a 12-week liraglutide trial, though the effect was present at 10 days and gone by week 12 even with treatment continuing.2 A 2025 review of the mechanism proposes that peripheral GLP-1 signaling reaches the nucleus tractus solitarius in the brainstem, which projects to GABA neurons in the ventral tegmental area, the hub that supplies dopamine to the reward circuit. The review proposes that GLP-1 signaling may modulate dopamine differently during reward anticipation and consumption, but the supporting evidence is preclinical and the split has not been confirmed in clinical populations.7
| Circuit node | What it does in appetite | Evidence for GLP-1 involvement |
|---|---|---|
| Insula | Encodes the salience and interoceptive weight of a food cue | Reduced activation to food pictures at 10 days on liraglutide, not sustained at 12 weeks2 |
| Amygdala | Assigns emotional value to a cue | Altered activation with GLP-1 receptor activation in a 48-person imaging trial6 |
| Nucleus tractus solitarius to ventral tegmental area | Brainstem relay proposed to dampen mesolimbic dopamine output | Proposed pathway from preclinical and review evidence, not directly confirmed in human circuitry7 |
| Orbitofrontal cortex | Values a food cue relative to alternatives | Increased right orbitofrontal response only in the BMI- and weight-adjusted analysis at 3.0 mg. The unadjusted analysis found no change3 |
That last row is the one that keeps the mechanism honest. The 2016 liraglutide trial reported reduced parietal-cortex response with secondary insula and putamen findings. The 2019 trial found no change in the unadjusted analysis, then found increased right orbitofrontal activation after adjusting for BMI and weight at the obesity dose. The authors discussed a possible weight-loss plateau.123 A single mechanism story does not fit both results. The reward circuit's response to a GLP-1 drug looks state-dependent and time-dependent rather than a fixed dial that only turns one way.
03How GLP-1 drugs reach the reward circuit
GLP-1 drugs plausibly reach the reward circuit through more than one route, and the literature keeps these routes distinct even when marketing language blurs them.
The peripheral route runs through the gut and vagus nerve. GLP-1 receptor activation slows gastric emptying, which prolongs mechanical fullness signals reaching the brainstem, and it acts on vagal afferents that carry gut-fullness information upward. This is the route most directly demonstrated in human physiology and covered in GLP-1 receptor agonist.
The central route depends on GLP-1 receptors documented directly in human brain tissue, including the hypothalamus, parietal cortex, and medulla.1 Central receptor activation is one candidate explanation for changes in food-cue reactivity and reward-region activity, but receptor localization alone does not establish that an injected GLP-1 drug directly reaches those regions. The nucleus tractus solitarius to ventral tegmental area pathway sits inside this central route and is currently a proposed mechanism drawn from imaging and preclinical work rather than a pathway isolated and confirmed in a controlled human trial.7
The honest summary is that peripheral gastric-emptying and vagal signaling are well established, central GLP-1 receptor localization in human hypothalamus, medulla, and parietal cortex is documented, and separate human imaging studies show changes in activity during food-cue tasks.16 The specific claim that central GLP-1 action directly and durably suppresses dopamine-driven food reward in humans is plausible and partially imaged, not fully demonstrated as a stable, dose-independent effect. Distinguish receptor localization from activity changes in food-related regions, and distinguish both findings from a claim that GLP-1 drugs permanently recalibrate food reward.
04What GLP-1 discontinuation trials measured
Every major GLP-1 withdrawal trial was built to answer a weight and cardiometabolic question, not a food-noise question, and that design choice shapes what can honestly be said about the reward circuit after stopping.
The STEP 1 extension followed adults off semaglutide and lifestyle support for a year after 68 weeks on treatment and found regain of 11.6 percentage points of body weight, about two-thirds of the weight originally lost, alongside cardiometabolic markers drifting back toward baseline.8 SURMOUNT-4 randomized adults who had already lost weight on tirzepatide to continued drug or placebo and found the placebo group regained 14.0% of body weight over 52 weeks.9 Both trials are strong on the scale-weight question. Neither trial re-administered a food-craving or food-preoccupation instrument after discontinuation to test whether the reward-circuit quiet documented on treatment reappears, fades gradually, or tracks the weight curve at all.89
The closest available contrast comes from a trial that stayed on treatment rather than stopping it. A 2023 two-year follow-up of the STEP 5 trial found semaglutide sustained improvements in Control of Eating Questionnaire craving-control scores through 104 weeks compared with placebo.10 That result shows craving control can be sustained for two years with continued dosing. It does not show what happens to that same score in the weeks after the drug is withdrawn, because STEP 5 did not include an off-treatment arm.
| What the evidence shows | What it does not show |
|---|---|
| Weight and cardiometabolic markers regain substantially after semaglutide or tirzepatide withdrawal, tracked for 52 weeks in both trials89 | Whether food-craving or food-preoccupation scores return on the same timeline as weight, since withdrawal trials did not remeasure these instruments |
| Craving-control scores stay improved through 104 weeks of continued semaglutide treatment10 | Whether craving-control scores fall, and how fast, once semaglutide is stopped |
| Reward-region brain activation changes measurably within 10 to 17 days of starting a GLP-1 drug12 | Whether reward-region activation returns to pretreatment baseline within a comparable window after stopping |
The gap is not a minor footnote. The popular claim that "food noise comes back when you stop" remains an inference from mechanism and patient report. Weight-regain trials provide a randomized evidence base, while matching food-noise measurements after withdrawal are absent.89 The nutrition and muscle plan for stopping a GLP-1 and how to stop GLP-1s without rapid fat regain both cover the weight side of this transition in detail. Treat the food-noise side as plausible but unconfirmed by the same quality of evidence.
05How to track weight regain and food noise after stopping GLP-1s
Weight regain is a slow, cumulative measurement that takes weeks to show up clearly on a scale. A return of food-related thoughts, cravings, and grazing impulses is a subjective experience that may not track the scale, but withdrawal trials have not established its timing or frequency.89
Track them as related but separate signals, the same way GLP-1 appetite management separates the appetite win from the meal-structure skill that has to survive it.
06What to track when food noise changes
Food noise is useful exactly when it points to a lever a person or coach can change, and it stops being useful when it becomes a label that replaces a real assessment. Build tracking around behavior and pattern, not around the word itself.
| What to track | Why it beats the word alone | Where it points |
|---|---|---|
| Time of day food thoughts intensify | Distinguishes a structural meal-timing gap from a global appetite change | Move calories or protein earlier if the pattern is afternoon or evening |
| Frequency of unplanned eating episodes per week | Gives a countable trend instead of a mood-based impression | Rising frequency after a dose change or a missed dose is a signal worth logging, not judging |
| Whether episodes involve loss of control, secrecy, or distress | Separates ordinary hedonic pull from a pattern that needs clinical attention | Loss-of-control features point toward binge eating patterns, which needs different support than meal-structure coaching |
| Sleep hours the night before a bad food-noise day | Sleep debt independently raises ghrelin and cue reactivity | A short-sleep night is a confound to rule out before blaming medication status alone |
| Medication status and days since last dose or discontinuation | The strongest known lever given the mechanism evidence above | Rising noise after a dose reduction or stop warrants tracking. Its frequency and timing after discontinuation remain unestablished |
Two decision checks follow directly from the evidence gap described above. First, do not tell a patient or client that stable body weight after stopping a GLP-1 means their food noise is also still under control, since no trial has confirmed those two measures move together after discontinuation.89 Second, if food thoughts include loss of control, secrecy, or eating to the point of distress rather than ordinary increased interest in food, treat that as a signal for clinical evaluation rather than a coaching adjustment, regardless of what the scale shows that week.
Footnotes
Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes, a crossover, randomised, placebo-controlled trial. Diabetologia. 2016, 59(5), 954-965. DOI | PubMed
↩ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes. Diabetes Care. 2016, 39(2), 214-221. DOI | PubMed
↩Farr OM, Upadhyay J, Rutagengwa C, et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues. Diabetes Obes Metab. 2019, 21(11), 2459-2464. PubMed
↩Tronieri JS, Wadden TA, Walsh O, et al. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. Int J Obes (Lond). 2020, 44(2), 353-361. PubMed
↩Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025. DOI | PMC
↩van Bloemendaal L, IJzerman RG, ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014, 63(12), 4186-4196. DOI | PubMed
↩Krupa AJ. Curbing the appetites and restoring the capacity for satisfaction, the impact of GLP-1 agonists on the reward circuitry. Neuroscience Applied. 2025, 4, 105512. PMC
↩Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide, the STEP 1 trial extension. Diabetes Obes Metab. 2022, 24(8), 1553-1564. DOI | PMC
↩Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity, the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331(1), 38-48. DOI | PubMed
↩Wharton S, Batterham RL, Bhatta M, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023, 31(3), 703-715. DOI | PubMed
↩
